Human health and medicine

Tic disorder

Tic disorder: DSM-5-TR neurodevelopmental conditions with motor and/or vocal tics, covering Tourette syndrome, persistent (chronic) motor or vocal tic disorder, and provisional tic disorder, diagnosed by tic type, duration, and onset before age 18.

Ticagrelor

Ticagrelor (Brilinta) is an oral, reversible P2Y12 platelet inhibitor approved in 2011 for ACS, post-MI, high-risk CAD, and minor stroke/TIA, dosed 180 mg load then 90 mg twice daily, with bleeding and dyspnea as main adverse effects.

Tick-borne relapsing fever

Tick-borne relapsing fever (TBRF), also soft tick relapsing fever, is a Borrelia spirochete infection transmitted mainly by Ornithodoros ticks, causing recurrent fever episodes; distinct from louse-borne relapsing fever caused by Borrelia recurrentis.

Tickling

Tickling: touching the body to provoke laughter or squirming, divided into knismesis (light, feather-like) and gargalesis (heavy, laughter-inducing); self-tickle is suppressed by cerebellar prediction, and rats and great apes are ticklish too.

Oct 15, 2026

Ticlopidine

Ticlopidine, sold as Ticlid, is an oral antiplatelet drug of the thienopyridine class that irreversibly blocks the platelet ADP P2Y12 receptor; synthesized in 1972, it was superseded by clopidogrel.

Ticrynafen

Ticrynafen (tienilic acid, Selacryn, SKF 62698) is a withdrawn uricosuric diuretic antihypertensive approved in the US in 1979, distinguished by lowering serum uric acid, and withdrawn January 1980 for immunoallergic hepatitis linked to anti-LKM2 antibodies against CYP2C9.

Tidal volume

Tidal volume (VT, TV) is the air moved in one normal breath, about 500 mL or 7 mL/kg ideal body weight in adults; a static lung volume in spirometry and, in ARDS ventilation, limited to 4–8 mL/kg predicted body weight.

Sep 29, 2026

TIDieR checklist

The TIDieR checklist, or Template for Intervention Description and Replication, is a 12-item guideline published in 2014 for describing health interventions clearly enough to replicate.

Tietz syndrome

Tietz syndrome (TADS, Tietz albinism-deafness syndrome, OMIM 103500): rare autosomal dominant MITF basic-domain disorder with congenital profound bilateral sensorineural hearing loss and generalized albino-like hypopigmentation, allelic to Waardenburg syndrome type 2.

Tietze syndrome

Tietze syndrome, also known as Tietze's disease, is a benign, self-limiting inflammatory condition, first described in 1921, that causes painful swelling where an upper rib's cartilage meets the sternum.

Tifacogin

Tifacogin (rTFPI, SC-59735) is a recombinant, non-glycosylated human tissue factor pathway inhibitor with an extra N-terminal alanine, developed by Chiron/Pharmacia for sepsis; OPTIMIST and CAPTIVATE phase 3 trials showed no mortality benefit and increased bleeding, so development was discontinued.

Tifcemalimab

Tifcemalimab (icatolimab, TAB004/JS004), Junshi Biosciences' first-in-human humanized IgG4 anti-BTLA monoclonal antibody, blocks HVEM-BTLA checkpoint signaling; phase 3 trials in limited-stage SCLC and Hodgkin lymphoma.

Tigatuzumab

Tigatuzumab (CS-1008), also called anti-DR5 MoAb, is a humanized agonistic IgG1 antibody against death receptor 5 (TRAIL-R2/TNFRSF10B) developed by Daiichi Sankyo; safe in phase I/II trials but without significant antitumor efficacy, development stopped before phase III.

Tiger Balm

Tiger Balm (万金油) is a camphor-and-menthol topical pain-relief brand created by Aw Boon Haw and Aw Boon Par, trademarked 1909 from their father's Rangoon apothecary Eng Aun Tong, now sold in over 100 countries by Haw Par.

TIGER study

TIGER (Treatment In Geriatric Epilepsy Research) is a VA national retrospective study of new-onset epilepsy in veterans aged 66+, led by Mary Jo Pugh, documenting phenytoin-dominant, guideline-discordant prescribing and drug-interaction risk; distinct from the Scottish Tayside TIGER trial.

Tight hymenal ring

Tight hymenal ring (rigid hymen, tight introitus; ICD-11 LB42.3, ICD-10-CM N89.6): a constricted hymenal opening causing dyspareunia and tampon or penetration difficulty, distinct from imperforate hymen, managed with dilation or minor surgery.

Tigulixostat

Tigulixostat, also known by the development code LC350189, is a once-daily, selective xanthine oxidase inhibitor from LG Chem for lowering serum urate in gout, now in Phase 3 trials.

Tilactase

Tilactase, the INN for lactase (beta-galactosidase, CAS 9031-11-2, ATC A09AA04), is an oral fungal acid lactase from Aspergillus oryzae taken before dairy to relieve lactose intolerance symptoms.

Tilbroquinol

Tilbroquinol (7-bromo-5-methylquinolin-8-ol, CAS 7175-09-9, INN) is a halogenated 8-hydroxyquinoline contact amoebicide for intestinal amebiasis, used with tiliquinol as Intetrix; withdrawn in France and Saudi Arabia for hepatotoxicity.

Tildrakizumab

Tildrakizumab (Ilumya, Ilumetri) is a humanized IgG1 monoclonal antibody blocking the IL-23 p19 subunit, approved from 2018 for moderate-to-severe plaque psoriasis, dosed 100 mg subcutaneously every 12 weeks with an optional 200 mg dose.

TiLi-BONE study

TiLi-BONE (NCT07094568), Tirzepatide vs Liraglutide in Bone, a prospective observational cohort study by the National and Kapodistrian University of Athens comparing bone turnover markers (CTX, P1NP) and body composition in adults with BMI ≥40 kg/m² over 6 months.

Tilsotolimod

Tilsotolimod (IMO-2125) is a synthetic Toll-like receptor 9 agonist oligonucleotide developed by Idera Pharmaceuticals for intratumoral injection with checkpoint inhibitors in anti-PD-1 refractory melanoma; the phase 3 ILLUMINATE-301 trial failed, and development was discontinued in December 2021.

Tilt table test

Tilt table test (head-up tilt, HUTT): a diagnostic procedure tilting a strapped patient to about 70 degrees while monitoring blood pressure and heart rhythm to evaluate unexplained syncope, vasovagal syncope, orthostatic hypotension, and POTS.

Tiludronic acid

Tiludronic acid (tiludronate, SR 41319, Skelid, Tildren) is a first-generation non-nitrogen bisphosphonate inhibiting osteoclasts, FDA-approved in 1997 for Paget's disease and used intravenously for navicular syndrome in horses.

Tim Ferriss

Tim Ferriss (Timothy Ferriss, born 1977), American author of The 4-Hour Workweek and The 4-Hour Body, host of The Tim Ferriss Show podcast, and angel investor in Uber, Facebook, and Twitter; distinct from science writer Timothy Ferris.

Tim Friede

Tim Friede, Wisconsin former truck mechanic and self-taught herpetologist, self-immunized against snake venom 2001-2018 (202 bites, hundreds of injections); his antibodies enabled Centivax and Columbia's experimental broad-spectrum antivenom published in Cell, 2025.